{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:08:56Z","timestamp":1779894536855,"version":"3.53.1"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Guillain\u2013Barr\u00e9 syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are immune-mediated inflammatory neuropathies characterized by T cell\u2013 and\/or autoantibody-driven injury to peripheral nerves. Although intravenous immunoglobulin (IVIg) is effective in both conditions, its use is limited by high dosing requirements, supply constraints, and manufacturing complexity. NVG-2089 is a recombinant IgG1 Fc-domain protein engineered to selectively agonize type II Fc receptors, promoting anti-inflammatory signaling through expansion of regulatory T cells (Tregs) and upregulation of the inhibitory Fc\u03b3 receptor Fc\u03b3RIIB. Its efficacy in immune complex\u2013mediated disease and T cell\u2013driven neuroinflammation prompted evaluation of its therapeutic potential in an animal model of inflammatory demyelinating neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a randomized, blinded preclinical study in the spontaneous autoimmune peripheral polyneuropathy model, a well-established murine model of inflammatory demyelinating neuropathy. Animals were treated with NVG-2089, high-dose IVIg, or vehicle. Outcomes included behavioral performance, nerve electrophysiology, peripheral nerve morphometrics, immunohistochemistry, and flow cytometric immunophenotyping.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both NVG-2089 and IVIg stabilized motor and sensory performance, preserved compound muscle action potential (CMAP) amplitudes, and attenuated demyelination-associated prolongation of distal latency and CMAP duration. Morphometric analyses demonstrated preservation of myelinated fiber density and normalization of g-ratio distributions in both treatment groups. Immunophenotyping indicated an expansion of functionally activated CD25\n                      <jats:sup>+<\/jats:sup>\n                      CD39\n                      <jats:sup>+<\/jats:sup>\n                      Tregs in the spleen, along with increased Fc\u03b3RIIB expression on B cells, monocytes, and dendritic cells across systemic and nerve-associated compartments, consistent with engagement of shared anti-inflammatory pathways.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NVG-2089 demonstrated robust neuroprotective efficacy comparable to IVIg while requiring a substantially lower protein dose. These findings support NVG-2089 as a promising, dose-efficient alternative to IVIg for the treatment of inflammatory demyelinating neuropathies, including GBS and CIDP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1857016","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:46:40Z","timestamp":1779893200000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy"],"prefix":"10.3389","volume":"17","author":[{"given":"Husniye G.","family":"Otlu","sequence":"first","affiliation":[{"name":"Neuromuscular Research Laboratory, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston","place":["Houston, TX, United States"]},{"name":"Vocational Health Sciences, Laboratory Techniques Program, Malatya Turgut Ozal University","place":["Malatya, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Gao","sequence":"additional","affiliation":[{"name":"Neuromuscular Research Laboratory, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg P.","family":"Coffey","sequence":"additional","affiliation":[{"name":"Nuvig Therapeutics","place":["Menlo Park, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Bright","sequence":"additional","affiliation":[{"name":"Nuvig Therapeutics","place":["Menlo Park, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa M. A.","family":"Toda","sequence":"additional","affiliation":[{"name":"Nuvig Therapeutics","place":["Menlo Park, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela B.","family":"Conley","sequence":"additional","affiliation":[{"name":"Nuvig Therapeutics","place":["Menlo Park, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazim","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Neuromuscular Research Laboratory, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Neuromuscular Research Laboratory, Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-barre syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06916-6","article-title":"Autoreactive T cells target peripheral nerves in Guillain-Barre syndrome","volume":"626","author":"Sukenikova","year":"2024","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ana.410090704","article-title":"Pathology of the guillain-barre syndrome","volume":"9","author":"Prineas","year":"1981","journal-title":"Ann Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00005792-196905000-00001","article-title":"The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis","volume":"48","author":"Asbury","year":"1969","journal-title":"Med (Baltimore)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ncl.2013.01.005","article-title":"Guillain-Barre syndrome and variants","volume":"31","author":"Dimachkie","year":"2013","journal-title":"Neurol Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00467-y","article-title":"Guillain-Barre syndrome in low-income and middle-income countries: Challenges and prospects","volume":"17","author":"Papri","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200010)48:4<624::aid-ana9>3.0.co;2-o","article-title":"Axonal Guillain-Barre syndrome: Relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan","volume":"48","author":"Ogawara","year":"2000","journal-title":"Ann Neurol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.40.12.1900","article-title":"Acute axonal polyneuropathy associated with anti-Gm1 antibodies following Campylobacter enteritis","volume":"40","author":"Yuki","year":"1990","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12974-021-02113-2","article-title":"The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Hagen","year":"2021","journal-title":"J Neuroinflamm"},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41572-018-0027-2","article-title":"Immune-mediated neuropathies","volume":"4","author":"Kieseier","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barre syndrome: A systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13613-025-01464-w","article-title":"Critical insights for intensivists on Guillain-Barre syndrome","volume":"15","author":"Weiss","year":"2025","journal-title":"Ann Intensive Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30202-3","article-title":"Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (Forcidp trial): A double-blind, multicentre, randomised controlled trial","volume":"17","author":"Hughes","year":"2018","journal-title":"Lancet Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1038411","article-title":"Sex differences in Guillain Barre syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis","volume":"13","author":"McCombe","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2010.00284.x","article-title":"Chronic inflammatory demyelinating polyneuropathy disease activity status: Recommendations for clinical research standards and use in clinical practice","volume":"15","author":"Gorson","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"B16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s12974-021-02319-4","article-title":"Global, regional, and national burden of Guillain-Barre syndrome and its underlying causes from 1990 to 2019","volume":"18","author":"Bragazzi","year":"2021","journal-title":"J Neuroinflamm"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2174\/156652409789839116","article-title":"Sexual dimorphism in autoimmune disease","volume":"9","author":"McCombe","year":"2009","journal-title":"Curr Mol Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4933-7-4","article-title":"The effect of ageing on human lymphocyte subsets: Comparison of males and females","volume":"7","author":"Yan","year":"2010","journal-title":"Immun Ageing"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28265","article-title":"Intravenous immunoglobulin and plasma exchange prescribing patterns for Guillain-Barre syndrome in the United States-2001 to 2018","volume":"70","author":"Stino","year":"2024","journal-title":"Muscle Nerve"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2022-003655","article-title":"Immunoglobulin use in neurology: A practical approach","volume":"25","author":"Kapoor","year":"2025","journal-title":"Pract Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172980","article-title":"An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with I.V. immunoglobulin","volume":"134","author":"Sneed","year":"2024","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/vox.70052","article-title":"Understanding supply sustainability of plasma-derived medicinal products: Drivers and consequences of shortages","volume":"120","author":"Belmonte","year":"2025","journal-title":"Vox Sang"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000529110","article-title":"Adverse reactions associated with intravenous immunoglobulin administration in the treatment of neurological disorders: A systematic review","volume":"184","author":"Jiang","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133571","article-title":"Intravenous immunoglobulin-induced aseptic meningitis-a narrative review of the diagnostic process, pathogenesis, preventative measures and treatment","volume":"11","author":"Kretowska-Grunwald","year":"2022","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008742","article-title":"Thromboembolic risk with Ivig: Incidence and risk factors in patients with inflammatory neuropathy","volume":"94","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/voxs.12037","article-title":"The mechanisms of action of Ivig in autoimmune and inflammatory diseases","volume":"2013","author":"Patil","year":"2013","journal-title":"ISBT Sci Ser"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123597","article-title":"Multicenter experience with efgartigimod in the treatment of anti-Nmdar encephalitis compared with Ivig and Spa-Ia during acute attacks","volume":"371","author":"Liu","year":"2025","journal-title":"Life Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01108-4","article-title":"Update on intravenous immunoglobulin in neurology: Modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic Ivig therapy","volume":"18","author":"Dalakas","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129594","article-title":"Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation","volume":"313","author":"Kaneko","year":"2006","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.adv2927","article-title":"The anti-inflammatory activity of IgG is enhanced by co-engagement of type I and Ii Fc receptors","volume":"390","author":"Jones","year":"2025","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1505292112","article-title":"Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type Ii Fcrs","volume":"112","author":"Fiebiger","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/s0092-8674(00)80337-2","article-title":"Deletion of Ship or Shp-1 reveals two distinct pathways for inhibitory signaling","volume":"90","author":"Ono","year":"1997","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nri2762","article-title":"Fcgammariib in autoimmunity and infection: Evolutionary and therapeutic implications","volume":"10","author":"Smith","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fcgamma receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220250","article-title":"Elimination of activating Fcgamma receptors in spontaneous autoimmune peripheral polyneuropathy model protects from neuropathic disease","volume":"14","author":"Zhang","year":"2019","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev-immunol-051116-052433","article-title":"Signaling by antibodies: Recent progress","volume":"35","author":"Bournazos","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.5.677","article-title":"Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient Nod mice","volume":"194","author":"Salomon","year":"2001","journal-title":"J Exp Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"5408","DOI":"10.1038\/s41598-018-23607-9","article-title":"Systemic Igf-1 gene delivery by Raav9 improves spontaneous autoimmune peripheral polyneuropathy (Sapp)","volume":"8","author":"Gao","year":"2018","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/ilar\/ilt054","article-title":"Animal models of autoimmune neuropathy","volume":"54","author":"Soliven","year":"2014","journal-title":"ILAR J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1466-4","article-title":"Inflammatory neuropathies: Pathology, molecular markers and targets for specific therapeutic intervention","volume":"130","author":"Ubogu","year":"2015","journal-title":"Acta Neuropathol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jaut.2016.09.003","article-title":"Guillain Barre syndrome is induced in non-obese diabetic (Nod) mice following Campylobacter jejuni infection and is exacerbated by antibiotics","volume":"77","author":"St Charles","year":"2017","journal-title":"J Autoimmun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.12.8753","article-title":"Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy","volume":"181","author":"Kim","year":"2008","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1529-8027.2012.00375.x","article-title":"Behavioral, electrophysiological, and histopathological characterization of a severe murine chronic demyelinating polyneuritis model","volume":"17","author":"Ubogu","year":"2012","journal-title":"J Peripher Nerv Syst"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1487788","article-title":"Differential regulation of tissue-resident and blood-derived macrophages in models of autoimmune and traumatic peripheral nerve injury","volume":"15","author":"Sprenger-Svacina","year":"2024","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00284","article-title":"Methods used to evaluate pain behaviors in rodents","volume":"10","author":"Deuis","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002937","article-title":"Long-term tactile hypersensitivity after nerve crush injury in mice is characterized by the persistence of intact sensory axons","volume":"164","author":"Kim","year":"2023","journal-title":"Pain"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2363880","article-title":"Probiotics and microbial metabolites maintain barrier and neuromuscular functions and clean protein aggregation to delay disease progression in Tdp43 mutation mice","volume":"16","author":"Zhang","year":"2024","journal-title":"Gut Microbes"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23710","article-title":"Monocarboxylate transporter 1 in Schwann cells contributes to maintenance of sensory nerve myelination during aging","volume":"68","author":"Jha","year":"2020","journal-title":"Glia"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2024.114774","article-title":"Rejuvenating fecal microbiota transplant enhances peripheral nerve repair in aged mice by modulating endoneurial inflammation","volume":"376","author":"Svacina","year":"2024","journal-title":"Exp Neurol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3791\/56538","article-title":"Analysis of immune cells in single sciatic nerves and dorsal root ganglion from a single mouse using flow cytometry","volume":"130","author":"Hidmark","year":"2017","journal-title":"J Vis Exp"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.12.006","article-title":"Signaling through the inhibitory Fc receptor Fcgammariib induces Cd8(+) T cell apoptosis to limit T cell immunity","volume":"52","author":"Morris","year":"2020","journal-title":"Immunity"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1101383","article-title":"Unilateral sciatic nerve crush induces white blood cell infiltration of the contralateral nerve","volume":"2022","author":"Cheng","year":"2022","journal-title":"J Healthc Eng"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2281-10.2010","article-title":"Passive transfer of IgG anti-Gm1 antibodies impairs peripheral nerve repair","volume":"30","author":"Lopez","year":"2010","journal-title":"J Neurosci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.expneurol.2016.05.020","article-title":"Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury","volume":"282","author":"Zhang","year":"2016","journal-title":"Exp Neurol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16073","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barre syndrome","volume":"30","author":"van Doorn","year":"2023","journal-title":"Eur J Neurol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-010-9407-4","article-title":"Ivig treatment and prognosis in Guillain-Barre syndrome","author":"van Doorn","year":"2010","journal-title":"J ClinImmunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30144-9","article-title":"Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Bunschoten","year":"2019","journal-title":"Lancet Neurol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.645263","article-title":"The cost effectiveness of immunoglobulin vs. hematopoietic stem cell transplantation for Cidp","volume":"12","author":"Burt","year":"2021","journal-title":"Front Neurol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.04.002","article-title":"Intravenous immunoglobulin: Mechanism of action in autoimmune and inflammatory conditions","volume":"11","author":"Bayry","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1242860","article-title":"Mechanism underlying polyvalent IgG-induced regulatory T cell activation and its clinical application: Anti-idiotypic regulatory T cell theory for immune tolerance","volume":"14","author":"Victor","year":"2023","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2023.103977","article-title":"High doses of intravenous immunoglobulin stimulate regulatory T cell and suppress natural killer cell in women with recurrent pregnancy loss","volume":"158","author":"Yamada","year":"2023","journal-title":"J Reprod Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nature10134","article-title":"Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway","volume":"475","author":"Anthony","year":"2011","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.59.12_suppl_6.s13","article-title":"Mechanisms of action of Ivig and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies","volume":"59","author":"Dalakas","year":"2002","journal-title":"Neurology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2174\/157015909790031166","article-title":"Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies","volume":"7","author":"Jacob","year":"2009","journal-title":"Curr Neuropharmacol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810163105","article-title":"Identification of a receptor required for the anti-inflammatory activity of Ivig","volume":"105","author":"Anthony","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2215153","article-title":"Progress in Guillain-Barre syndrome immunotherapy-a narrative review of new strategies in recent years","volume":"19","author":"Yao","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B67","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1529-8027.2008.00158.x","article-title":"Impairment of circulating Cd4+Cd25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"13","author":"Chi","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2007.09.034","article-title":"Abnormality of circulating Cd4(+)Cd25(+) regulatory T cell in patients with Guillain-Barre syndrome","volume":"192","author":"Chi","year":"2007","journal-title":"J Neuroimmunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-468264","article-title":"Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells","volume":"122","author":"Trinath","year":"2013","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00197","article-title":"Differences in anti-inflammatory actions of intravenous immunoglobulin between mice and men: More than meets the eye","volume":"6","author":"Tjon","year":"2015","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jaut.2014.12.007","article-title":"The expression of Cd39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation","volume":"58","author":"Rissiek","year":"2015","journal-title":"J Autoimmun"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2016.30","article-title":"Human Cd39(Hi) regulatory T cells present stronger stability and function under inflammatory conditions","volume":"14","author":"Gu","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by Cd39 and Cd73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J Exp Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401434","article-title":"Regulatory T cell-derived adenosine induces dendritic cell migration through the Epac-Rap1 pathway","volume":"194","author":"Ring","year":"2015","journal-title":"J Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901881","article-title":"Cd39+Foxp3+ regulatory T cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis","volume":"183","author":"Fletcher","year":"2009","journal-title":"J Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157250","article-title":"Fcgammariib regulates autoantibody responses by limiting marginal zone B cell activation","volume":"132","author":"Barlev","year":"2022","journal-title":"J Clin Invest"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/114.1.429","article-title":"Chronic relapsing experimental allergic neuritis induced by repeated transfer of P2-protein reactive T cell lines","volume":"114","author":"Lassmann","year":"1991","journal-title":"Brain"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2014.11.022","article-title":"Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies","volume":"278","author":"Brun","year":"2015","journal-title":"J Neuroimmunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.10879","article-title":"Biphasic form of experimental autoimmune neuritis in Dark Agouti rats and its oral therapy by antigen-specific tolerization","volume":"75","author":"Jung","year":"2004","journal-title":"J Neurosci Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1857016\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:46:42Z","timestamp":1779893202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1857016\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2026.1857016"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1857016","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"article-number":"1857016"}}